Nuevolution reels in €11 million for discovery work; Pfizer ditches online trial recruitment for study;

@FierceBiotech: The Fierce team has landed in Boston. Check out our dedicated BIO2012 page. Special Coverage | Follow @FierceBiotech

@JohnCFierce: Thanks to Bernard Munos, Jim Burns, Jason Gardner, Jill Milne, Mene Pangalos and 300+ of my closest friends for a great conversation this a.m. | Follow @JohnCFierce

@RyanMFierce: FDA has shot down Pfizer's bid for approval of TTR-FAP rare disease drug. News | Follow @RyanMFierce

> Danish drug discovery group Nuevolution has brought in €11 million in new financing from Industrifonden and repeat backers Sunstone Capital, SEB Venture Capital and SEB Utvecklingsstiftelse. Release

> The FDA and EMA granted orphan drug status to bluebird bio's experimental gene therapy for adrenoleukodystrophy, which is also known as Lorenzo's Oil disease. Release

> Pharmalot's Ed Silverman reports that Pfizer ($PFE) has pulled the plug on an effort to recruit patients for clinical trials with social media and computer technologies. News

> XTL Biopharmaceuticals revealed plans to scoop up Kitov Pharmaceuticals for shares and cash milestones that could reach $48 million. Item

> British biotech Heptares Therapeutics has extended its collaboration with the UK Medical Research Council to study the structure of transmembrane proteins. Release

Pharma News

@FiercePharma: Will Human Genome's bid deadline backfire? Or will $GSK be thwarted by some secretive white knight? Report | Follow @FiercePharma

> With Brennan gone, AstraZeneca megamerger talk can resume. Article

> No overtime for pharma reps, Supreme Court says. Story

> Merck Serono's final answer: Geneva HQ will close. News

Medical Devices News

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

 @MarkHFierce: Our coverage of the 2012 BIO International Convention continues. Roundup | Follow @MarkHFierce

> Medical device/Dx VC funding has gotten 'a little' better. Report

> China Medical's investors petition for liquidation. News

> At BIO, experts rethink how to make companion diagnostics viable. Article

> A declining rupee could spell trouble for India's medical equipment imports. Item

Biotech Research News

> In life sciences R&D, China is reaching for the stars. Editor's corner

> Pluristem's placental stem cells spur bone marrow growth. Story

> Genetic markers uncovered for rare children's brain tumor. Report

> Breakthrough: Human Microbiome Project maps healthy body microbes. More

Pharma Manufacturing News

> Amneal Pharmaceuticals quadruples manufacturing. Item

> Just about everyone agrees: drug shortages are a complex puzzle. Story

> Canadian Internet pharmacy leader faces federal charges. Article

And Finally… A study suggests that getting rays could reduce a person's risk of getting pancreatic cancer. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.